Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO GU 2019 renal highlights

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 14.02.19
Views: 1841
Rating:

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

Dr Toni Choueiri speaks to ecancer at the 2019 ASCO Genitourinary Cancers Symposium providing highlights from the renal cancer research at year's conference.

He provides data from some of the most important studies, and emerging combinations in renal cancer.

The remainder of Dr Choueiri's highlights cover MET inhibitors and PDL-1 inhibitors in non-clear cell renal carcinoma.

Finally he emphasises the quality of the research across the board, and invites listeners to delve further into some of the results from this year's ASCO GU.

Related videos

follow us

WIN 2019


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation